New drug cocktail shows promise in early CLL trial
NCT ID NCT02158091
First seen Feb 15, 2026 · Last updated May 01, 2026 · Updated 10 times
Summary
This study tests a new drug called IPI-145 combined with standard chemotherapy (FCR) in 32 younger adults (ages 18-65) with untreated chronic lymphocytic leukemia (CLL). The goal is to see if the combination is safe and can make the cancer disappear from the bone marrow (called MRD-negative remission). This is an early-phase trial, so it focuses on safety and finding the best dose, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Isreal Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.